Baseline demographics: MRD-evaluable subset (full analysis set, N = 225)
| Characteristic . | . | |||
|---|---|---|---|---|
| MRD complete responders (n = 64), n (%) . | MRD responders (n = 75), n (%) . | MRD nonresponders (n = 15), n (%) . | Overall MRD evaluable (N = 90), n (%) . | |
| Age group, y | ||||
| 18 to <35 | 30 (46.9) | 33 (44.0) | 6 (40.0) | 39 (43.3) |
| 35 to <55 | 19 (29.7) | 20 (26.7) | 4 (26.7) | 24 (26.7) |
| 55 to <65 | 7 (10.9) | 11 (14.7) | 2 (13.3) | 13 (14.4) |
| ≥65 | 8 (12.5) | 11 (14.7) | 3 (20.0) | 14 (15.6) |
| Prior salvage therapies, n | ||||
| 0 | 18 (28.1) | 19 (25.3) | 3 (20.0) | 22 (24.4) |
| 1 | 27 (42.2) | 32 (42.7) | 9 (60.0) | 41 (45.6) |
| 2 | 12 (18.7) | 14 (18.7) | 0 (0.0) | 14 (15.6) |
| >2 | 7 (10.9) | 10 (13.3) | 3 (20.0) | 13 (14.4) |
| Disease stage | ||||
| Primary refractory | 7 (10.9) | 9 (12.0) | 1 (6.7) | 10 (11.1) |
| First salvage with first remission ≤12 mo | 8 (12.5) | 8 (10.7) | 2 (13.3) | 10 (11.1) |
| Relapse ≤12 mo of allogeneic HSCT | 12 (18.8) | 13 (17.3) | 3 (20.0) | 16 (17.8) |
| Bone marrow blast count, %* | ||||
| <50 | 32 (50.0) | 41 (54.7) | 4 (26.7) | 45 (50.0) |
| ≥50 | 32 (50.0) | 34 (45.3) | 11 (73.3) | 45 (50.0) |
| Characteristic . | . | |||
|---|---|---|---|---|
| MRD complete responders (n = 64), n (%) . | MRD responders (n = 75), n (%) . | MRD nonresponders (n = 15), n (%) . | Overall MRD evaluable (N = 90), n (%) . | |
| Age group, y | ||||
| 18 to <35 | 30 (46.9) | 33 (44.0) | 6 (40.0) | 39 (43.3) |
| 35 to <55 | 19 (29.7) | 20 (26.7) | 4 (26.7) | 24 (26.7) |
| 55 to <65 | 7 (10.9) | 11 (14.7) | 2 (13.3) | 13 (14.4) |
| ≥65 | 8 (12.5) | 11 (14.7) | 3 (20.0) | 14 (15.6) |
| Prior salvage therapies, n | ||||
| 0 | 18 (28.1) | 19 (25.3) | 3 (20.0) | 22 (24.4) |
| 1 | 27 (42.2) | 32 (42.7) | 9 (60.0) | 41 (45.6) |
| 2 | 12 (18.7) | 14 (18.7) | 0 (0.0) | 14 (15.6) |
| >2 | 7 (10.9) | 10 (13.3) | 3 (20.0) | 13 (14.4) |
| Disease stage | ||||
| Primary refractory | 7 (10.9) | 9 (12.0) | 1 (6.7) | 10 (11.1) |
| First salvage with first remission ≤12 mo | 8 (12.5) | 8 (10.7) | 2 (13.3) | 10 (11.1) |
| Relapse ≤12 mo of allogeneic HSCT | 12 (18.8) | 13 (17.3) | 3 (20.0) | 16 (17.8) |
| Bone marrow blast count, %* | ||||
| <50 | 32 (50.0) | 41 (54.7) | 4 (26.7) | 45 (50.0) |
| ≥50 | 32 (50.0) | 34 (45.3) | 11 (73.3) | 45 (50.0) |
There was no statistically significant difference for any characteristic in the comparison of MRD responders and nonresponders.
Based on central laboratory assessment.